IMS Health Study: Low Levels of Adherence and Persistence Remain Barriers to Reducing the Costs of Diabetes Complications
12 Juillet 2016 - 3:00PM
Business Wire
Up to 15 Percent of Healthcare System Costs
Avoidable; Effective Patient Activation by Multiple Stakeholders
Key to Driving Improvement
Despite improved diagnosis and advances in treatment options for
individuals with Type 2 Diabetes, sub-optimal therapy adherence and
persistence result in significant economic and societal burden as
well as avoidable patient complications in six diverse healthcare
systems around the world, according to a new report series issued
today by the IMS Institute for Healthcare Informatics. Disease
complications account for an estimated 61 – 80 percent of Type 2
Diabetes-related costs in the countries studied, with 4 – 15
percent of costs linked to poor adherence and persistence.
Effective patient activation—how well people understand their role
in the care process along with their ability and willingness to
actively manage their own health and care—is key to deriving
greater value from existing diabetes treatments.
The report series—Improving Type 2 Diabetes Therapy Adherence
and Persistence: How to Address Avoidable Economic and Societal
Burden—analyzes the unique epidemiology, local healthcare dynamics
and drivers for adherence and persistence in Brazil, Germany, the
Kingdom of Saudi Arabia, Mexico, the U.K. and the U.S. Avoidable
Type 2 Diabetes costs due to diabetes-related complications were
determined using IMS Health’s CORE Diabetes Model, a validated,
peer-reviewed algorithm that simulates clinical outcomes and costs
for cohorts of people with the condition.
The reports highlight a number of practical, actionable
recommendations to raise levels of adherence and persistence in
Type 2 Diabetes therapies that span diet, exercise and use of
glucose-lowering medicines. They include identifying and profiling
patients in need of help; improving access to customized education
materials; maximizing engagement between healthcare providers and
patients; and using digital technology to maintain effective
disease self management.
“The rising prevalence of Type 2 Diabetes and its associated
complications is the root of considerable strain on society and an
economic burden on healthcare systems,” said Murray Aitken, IMS
Health senior vice president and executive director of the IMS
Institute for Healthcare Informatics. “Simple, customized
interventions that put patients on the path to optimal adherence
and persistence can yield tangible results, but require alignment
between healthcare and government leaders, as well as the active
involvement of voluntary associations and the private sector.”
Key findings of the report series include the following:
- Sub-optimal adherence and
persistence is a significant issue for people with diabetes. On
average, less than 40 percent of individuals with Type 2 Diabetes
globally are achieving optimal levels of adherence (the extent to
which a patient follows the prescribed interval and dose of a
medicine regimen) and persistence (the time from initiation to
discontinuation of a therapy). Among the six countries studied,
levels of non-adherence vary significantly and the Institute's
estimates range from 46 to 77 percent. The reports found that
current strategies to improve Type 2 Diabetes outcomes in these
countries were not directly focused on addressing sub-optimal
therapy adherence and persistence.
- Complications from diabetes lead to
a significant increase in comorbidities and associated healthcare
costs. Undetected or poorly managed Type 2 Diabetes resulting
in persistently elevated blood glucose levels increases the risk of
long-term debilitating and life-threatening complications. These
include macrovascular comorbidities such as stroke and myocardial
infarction, as well as microvascular damage that presents as
nephropathy, foot ulcers leading to amputations and retinopathy
leading to blindness. Beyond these long-term conditions, near-term
complications can include lethargy, poor wound healing and a
propensity for opportunistic infections. All of these health
consequences can vastly decrease quality of life, productivity and
life expectancy of people with diabetes while increasing lifelong
healthcare costs.
- Improved adherence and persistence
can reduce costs of complications by 4 -15 percent. Estimates
of the potential reduction in Diabetes Type 2 complications costs
for each country studied were derived using IMS Health’s CORE
Diabetes Model, customized to reflect average levels of adherence
and persistence. For the U.S. Medicare population, this approach
yielded an estimated $4 billion annual avoidable cost, which is
equal to about 32 percent of the total annual Medicare spend on
diabetes medications and supplies—or 4 percent of the total spend
on all diabetes care for seniors. In Saudi Arabia, avoidable costs
were estimated at more than 15 percent of total complications
costs, or approximately SAR3.9 billion per year.
- Greater patient activation is
directly linked to increases in therapy adherence and lower
healthcare costs. Patient costs can vary more than 20 percent
depending on the level of patient activation, according to recent
research. Five interrelated drivers of activation are: health
beliefs and attitude; personal circumstances; health status; health
literacy; as well as access and affordability. Together, these
factors determine an individual’s willingness and ability to take
actions to manage their own health. For example, improving health
literacy may positively impact health beliefs and attitude,
enabling a patient to identify opportunities for overcoming
barriers to access and affordability.
- Effective patient activation
requires multi-stakeholder engagement. The path to optimal
adherence and persistence involves policymakers, payers, healthcare
providers, the private sector, caregivers, families and patients
themselves. Policymakers can play a vital role in addressing
barriers in the integration and provision of care by improving
access, health literacy, health beliefs and attitudes.
Multi-stakeholder involvement ultimately enables healthcare
providers to address an individual’s specific support and
information needs through a customized, patient-centric
approach.
The report series, including a detailed description of
methodologies, are available at www.theimsinstitute.org. This study
is based on research and analysis undertaken by the IMS Consulting
Group with support from Lilly Diabetes.
About the IMS Institute for Healthcare Informatics
The IMS Institute for Healthcare Informatics provides key policy
setters and decision makers in the global health sector with unique
and transformational insights into healthcare dynamics derived from
granular analysis of information. It is a research-driven entity
with a worldwide reach that collaborates with external healthcare
experts from across academia and the public and private sectors to
objectively apply IMS Health’s proprietary global information and
analytical assets. More information about the IMS Institute can be
found at: http://www.theimsinstitute.org.
About IMS Health
IMS Health is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our
7,000 services experts connect configurable SaaS applications to
15+ petabytes of complex healthcare data in the IMS One™ cloud
platform, delivering unique insights into diseases, treatments,
costs and outcomes. The company’s 15,000 employees blend global
consistency and local market knowledge across 100 countries to help
clients run their operations more efficiently. Customers include
pharmaceutical, consumer health and medical device manufacturers
and distributors, providers, payers, government agencies,
policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS
Health uses anonymous healthcare data to deliver critical,
real-world disease and treatment insights. These insights help
biotech and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders to
identify unmet treatment needs and understand the effectiveness and
value of pharmaceutical products in improving overall health
outcomes. Additional information is available at
www.imshealth.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160712005431/en/
IMS HealthTor Constantino,
+1-484-567-6732tconstantino@us.imshealth.com
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024